Receptor News and Research

RSS

Endoscopic sleeve gastroplasty outperforms oral semaglutide in short-term weight loss

A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.

15 May 2026

New guidelines for identifying and treating high-risk IEC-HS patients

Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory disease. However, its clinical success is accompanied by a spectrum of immune-related toxicities, which remain a major challenge in practice.

15 May 2026

GLP-1 weight loss medications linked to significant drop in asthma flares

New research presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows the use of the new GLP-1 class of obesity drugs in people with asthma is associated with a 26 % fall in the number of asthma exacerbations and a 14% drop in use of asthma inhaler reliever use. The study is by Simon Høj and Dr Kjell Erik Julius Håkansson, Copenhagen University Hospital, Copenhagen, Denmark and colleagues.

15 May 2026

Study reveals why aging makes the body more vulnerable to breast cancer

Researchers at Georgetown's Lombardi Comprehensive Cancer Center have identified a mechanism that may help explain a key reason why older people experience worse outcomes from breast cancer.

15 May 2026

Study identifies breakthrough drug combination for early-stage Peyronie’s

Combining two widely prescribed drug classes could provide the first effective treatment for early-stage Peyronie's disease, according to a new study published in The Journal of Sexual Medicine.

15 May 2026

New obesity medications offer a potent tool for combating hypertension

A meta-analysis of 32 studies and 43,618 adults presented at this year's European Congress on Obesity in Istanbul, Turkey (12-15 May) shows that use of new classes of obesity drugs for weight loss is associated with a clinically relevant drop in blood pressure (BP): a 0.34 mmHg reduction in systolic BP per 1\% weight loss.

15 May 2026

Researchers develop pH and redox-sensitive systems to reduce immunotherapy toxicity

Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small subset of patients benefit. Many solid tumors remain "cold," characterized by poor immune cell infiltration and resistance to immune checkpoint blockade (ICB).

15 May 2026

Thyroid hormone profiles provide critical prognostic clues for patients facing liver failure

Early and accurate prognostic assessment is crucial to prevent disease progression in liver failure. Thyroid hormones (THs), particularly triiodothyronine (T3), are key metabolic regulators and play an important role in liver regeneration. Liver failure is frequently complicated by non‑thyroidal illness syndrome (NTIS), characterized by low T3 with normal or slightly elevated TSH and T4.

14 May 2026

A breakthrough molecular discovery could neutralize gluten and protect coeliac patients

A research project led by the Institute for Research in Nutrition and Food Safety (INSA) and the Faculty of Pharmacy and Food Sciences at the University of Barcelona, together with the Molecular Biology Institute of Barcelona (IBMB) of the CSIC (which stands for Consejo Superior de Investigaciones Científicas), has successfully designed and tested a gluten-degrading molecule that is a promising ally in the management of coeliac disease, an autoimmune disease whose symptoms are triggered by the consumption of gluten and other prolamins found in cereals.

14 May 2026

New imaging technique maps 38000 liver cells to solve fibrosis

The liver is often called a "silent organ," as it can sustain significant damage without obvious symptoms. But when injury is prolonged, whether from alcohol, poor diet, or chronic hepatitis virus infection, it triggers fibrosis: a progressive hardening and scarring of liver tissue.

14 May 2026

Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma

A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for glioblastoma, the most aggressive and most common type of primary brain cancer in adults.

13 May 2026

Semaglutide significantly reduces obesity in treatment-resistant young adults

A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

13 May 2026

GLP-1 obesity drugs mainly reduce fat while preserving muscle mass

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following treatment with GLP-1 drugs for obesity, most weight loss is fat mass (80–85%) and relative muscle mass is preserved.

13 May 2026

AI-based generative framework create all-atom models of proteins in motion

Many drug and antibody discovery pathways focus on intricately folded cell membrane proteins. When molecules of a drug candidate bind to these proteins, like a key going into a lock, they trigger chemical cascades that alter cellular behavior.

13 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Adding GLP-1 drugs to behavioral interventions silences food noise

New research presented at this year's European Congress on Obesity in Istanbul, Turkey, shows that use of obesity drugs alongside behavioral interventions leads to a larger drop in so called 'food noise' than in those using the behavioral therapy alone.

13 May 2026

Rhein protects against intestinal injury in severe acute pancreatitis

Severe acute pancreatitis (SAP) remains one of the most formidable challenges in gastrointestinal emergency medicine.

13 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026

Researchers map the brain histamine system to understand mental health

New research, from King's College London and the University of Porto, has mapped the histamine system in the brain. Histamine, a molecule more commonly associated with allergies, plays a separate but poorly understood role in brain function.

12 May 2026

INDIGO Biosciences expands reporter assay capabilities with new Transrepression Assay Services

INDIGO Biosciences today announced the launch of its Transrepression Assay Services, expanding the company’s cell-based reporter assay capabilities for drug discovery teams studying pathway cross-talk, selective modulation, and transcription factor-mediated gene suppression.

From INDIGO Biosciences, Inc. 11 May 2026